908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares’ Fully Integrated Cell Therapy Manufacturing Platform
29 Février 2024 - 1:00PM
Business Wire
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built
handheld and desktop devices for chemical and biochemical analysis,
and Cellares, the first Integrated Development and Manufacturing
Organization (IDMO) dedicated to clinical and commercial-scale cell
therapy manufacturing, announce a development collaboration to
integrate in-line monitoring of key cell culture parameters into
Cellares’ Cell Shuttle system, a fully integrated, scalable, cell
therapy manufacturing platform. The collaboration between the two
companies aims to further advance the efficiency, safety, and
cost-effectiveness of large-scale cell therapy manufacturing.
908 Devices is integrating its optical in-line analyzer,
MAVERICK, the first turn-key device to utilize Raman spectroscopy
for bioprocess control, with no modeling or development required.
MAVERICK’s purpose-built de novo models automatically process Raman
spectra from a wide variety of culture media types and cell lines,
delivering actionable process parameters or direct process control
actions. The company is adapting its MAVERICK device to be
integrated into the Cell Shuttle system.
“In-line analysis provides real-time monitoring of the cell
culture process, allowing for immediate corrective action. It also
maintains sample integrity, reduces contamination risk, and
improves product quality,” said Christopher D. Brown, PhD, Chief
Product Officer and Co-founder, 908 Devices. “We’re very proud to
partner with Cellares to accelerate access to life-saving cell
therapies.”
Cellares’ Cell Shuttle supports both autologous and allogeneic
cell therapy processes and most cell therapy modalities. The Cell
Shuttle platform integrates all the technologies required for all
unit operations and is successfully running CAR-T cell therapy
processes with true walk-away, end-to-end automation. Cellares’
Cell Shuttle reduces labor and facility size required by 90%
compared with manual cell therapy manufacturing processes based on
benchtop equipment. Consequently, Cellares’ IDMO Smart Factories
can produce 10 times more cell therapy batches per year than
conventional CDMO facilities, with the same footprint and the same
workforce.
“We are pleased to announce our collaboration with 908 Devices,”
said Daniele Malleo, PhD, Cellares VP of Research and Development.
“The integration of the 908’s MAVERICK Raman Spectrometer into
Cellares’ fully automated, closed end-to-end cell therapy
manufacturing platform will enable real-time process control of key
cellular parameters, enhancing the efficiency and safety of cell
therapy production while significantly reducing costs. This
collaboration is a testament to our vision of making advanced cell
therapies more accessible and affordable, ultimately accelerating
the delivery of these critical treatments to patients who need
them.”
About 908 Devices 908 Devices is revolutionizing chemical
and biochemical analysis with its simple handheld and desktop
devices, addressing critical-to-life applications. The Company’s
devices are used at the point-of-need to interrogate unknown and
invisible materials and provide quick, actionable answers to
directly address some of the most critical problems in life
sciences research, bioprocessing, pharma/biopharma, forensics and
adjacent markets. The Company is headquartered in the heart of
Boston, where it designs and manufactures innovative products that
bring together the power of mass spectrometry, microfluidic
sampling and separations, software automation, and machine
learning. To learn more, visit 908devices.com.
About Cellares Cellares is the first Integrated
Development and Manufacturing Organization (IDMO) and takes an
Industry 4.0 approach to mass manufacturing the living drugs of the
21st century. The company is both developing and operating
integrated technologies for cell therapy manufacturing to
accelerate access to life-saving cell therapies. The company's Cell
Shuttle integrates all the technologies required for the entire
manufacturing process in a flexible and high-throughput platform
that delivers true walk-away, end-to-end automation. Cell Shuttle
is being deployed in Cellares' Smart Factories around the world to
meet total patient demand for cell therapies at global scale.
Partnering with Cellares enables academics, biotechs, and pharma
companies to accelerate drug development and scale out
manufacturing, lower process failure rates, lower manufacturing
costs, and meet global patient demand.
The company is headquartered in South San Francisco, California,
with its commercial-scale IDMO Smart Factory in Bridgewater, New
Jersey. The company is backed by world-class investors and has
raised over $355 million in financing.
For more information about Cellares, please visit
cellares.com.
Forward Looking Statements for 908 Devices This
press release includes “forward looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements other than statements of historical facts are
forward-looking statements, including, without limitation,
statements regarding the expected uses and capabilities of the
Company’s products. Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “estimate,” “intend” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on
management’s current expectations and involve known and unknown
risks, uncertainties and assumptions which may cause actual results
to differ materially from any results expressed or implied by any
forward-looking statement, including the risks outlined under “Risk
Factors” and elsewhere in the Company’s filings with the Securities
and Exchange Commission which are available on the SEC's website at
www.sec.gov. Additional information will be made available in the
Company’s annual and quarterly reports and other filings that it
makes from time to time with the SEC. Although the Company believes
that the expectations reflected in its forward-looking statements
are reasonable, it cannot guarantee future results. The Company has
no obligation, and does not undertake any obligation, to update or
revise any forward-looking statement made in this press release to
reflect changes since the date of this press release, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229838986/en/
908 Devices Media Contact: Barbara Russo brusso@908devices.com
908 Devices Investor Contact: Carrie Mendivil IR@908devices.com
Cellares Media Contact: cellares@consortpartners.com
908 Devices (NASDAQ:MASS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
908 Devices (NASDAQ:MASS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024